These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35386180)

  • 1. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 4. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
    Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
    Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
    Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
    Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag.
    Abdelsamia M; Farid S; Dean S; Cataland SR
    Hematol Rep; 2023 Sep; 15(3):518-523. PubMed ID: 37754669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
    Agarwal N; Mangla A
    Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Ther Adv Hematol; 2019; 10():2040620719841735. PubMed ID: 31007886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments.
    Aiello A; Mariano EE; Prada M; Teruzzi C; Martone N; Capri S; Carli G; Siragusa S
    J Mark Access Health Policy; 2023; 11(1):2230663. PubMed ID: 37405228
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.
    Yassin MA; Al-Rasheed M; Al-Khaboori M; Marashi M; Osman H; Wali Y; Al Kindi S; Alsayegh F; Provan D
    Front Cardiovasc Med; 2023; 10():1260487. PubMed ID: 38162126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China.
    Mei H; Zhou H; Hou M; Sun J; Zhang L; Luo J; Jiang Z; Ye X; Xu Y; Lu J; Wang H; Hui A; Zhou Y; Hu Y
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102158. PubMed ID: 37700877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.